Compare PYXS & DLHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PYXS | DLHC |
|---|---|---|
| Founded | 2018 | 1969 |
| Country | United States | United States |
| Employees | N/A | 2300 |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 83.8M |
| IPO Year | 2021 | N/A |
| Metric | PYXS | DLHC |
|---|---|---|
| Price | $1.78 | $5.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.75 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 12.7K |
| Earning Date | 11-03-2025 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | $2,820,000.00 | ★ $344,497,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.81 |
| P/E Ratio | ★ N/A | $64.22 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.83 | $2.72 |
| 52 Week High | $5.55 | $8.25 |
| Indicator | PYXS | DLHC |
|---|---|---|
| Relative Strength Index (RSI) | 41.92 | 51.99 |
| Support Level | $1.03 | $5.51 |
| Resistance Level | $2.17 | $6.25 |
| Average True Range (ATR) | 0.20 | 0.21 |
| MACD | 0.16 | 0.04 |
| Stochastic Oscillator | 66.22 | 40.00 |
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
DLH Holdings Corp delivers health and readiness solutions for federal government customers through digital transformation and cyber security, science research and development, and systems engineering and integration. It provides technology-enabled business process, program management, and digital transformation solutions to U.S. government agencies, focusing on large-scale, technology-powered health and defense initiatives for agencies including HHS, VA, DoD, and their sub-agencies. Its revenues come from technology-enabled business process outsourcing, program management solutions, and public health research and analytics under time-and-materials, cost-reimbursable, and firm-fixed-price contracts.